A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.84 USD -4.66% Market Closed
Market Cap: 66.6m USD

Armata Pharmaceuticals Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Armata Pharmaceuticals Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Change in Working Capital
-$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$5.6B
CAGR 3-Years
-51%
CAGR 5-Years
-43%
CAGR 10-Years
-36%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
-$1.5B
CAGR 3-Years
-77%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
$2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
7%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$912.6m
CAGR 3-Years
-81%
CAGR 5-Years
-103%
CAGR 10-Years
-19%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
-$929.2m
CAGR 3-Years
-19%
CAGR 5-Years
-6%
CAGR 10-Years
-20%

Armata Pharmaceuticals Inc
Glance View

Market Cap
66.6m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
1.74 USD
Overvaluation 5%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
-1.6m USD

Based on the financial report for Mar 31, 2025, Armata Pharmaceuticals Inc's Change in Working Capital amounts to -1.6m USD.

What is Armata Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
14%

Over the last year, the Change in Working Capital growth was 60%.

Back to Top